Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Thomas Filleron"'
Autor:
Ivan Bièche, Catherine Guerin, Marta Jimenez, Céline Callens, Daniel Nenciu, Thomas Filleron, Nathalie Droin, Olivier Tredan, Kadija Diop, Andrea Loehr, Anthony Gonçalves, Monica Arnedos, Cecile Vicier, Fabrice Andre, Pascal Jézéquel, Marie-Paule Sablin, Anne Patsouris
Publikováno v:
European journal of cancer (Oxford, England : 1990). 159
Background Breast cancer may present genomic alterations leading to homologous recombination deficiency (HRD). PARP inhibitors have proven their efficacy in patients with HER2-negative (HER2-) metastatic breast cancer (mBC) harbouring germline (g) BR
Autor:
Loic Mourey, Christophe Massard, Remy Delva, Joseph Ciccolini, Fabienne Thomas, Christine Chevreau, Thomas Filleron, Jean-Pierre Lotz, Stéphane Culine, Gwenaelle Gravis, Marine Gross-Goupil, Etienne Chatelut, Aude Flechon, Angelo Paci, Jacques-Olivier Bay, Jérôme Guitton, Sotheara Moeung, Yohan Gallois, Pascale Olivier, Bénédicte Lelièvre, Karim Fizazi
Publikováno v:
Cancer Medicine
Cancer Medicine, Wiley, 2021, 10 (7), pp.2250-2258. ⟨10.1002/cam4.3687⟩
Cancer Medicine, Vol 10, Iss 7, Pp 2250-2258 (2021)
Cancer Medicine, Wiley, 2021, 10 (7), pp.2250-2258. ⟨10.1002/cam4.3687⟩
Cancer Medicine, Vol 10, Iss 7, Pp 2250-2258 (2021)
Background High‐dose chemotherapy (HDCT) with TI‐CE regimen is a valid option for the treatment of relapsed advanced germ cell tumors (GCT). We report a phase II trial with therapeutic drug monitoring of carboplatin for optimizing area under the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb4da192febd5a6e0225a744c30d9760
https://hal.univ-angers.fr/hal-03208728
https://hal.univ-angers.fr/hal-03208728
Autor:
Carine Dufau, Florent Dufour, Nicole Therville, Michel Record, Céline Colacios, Andrei Constantinescu, Thomas Filleron, Anne Montfort, Julia Rochotte, Joëlle Riond, Hervé Benoist, Thierry Levade, Nilton De França Junior, Caroline Imbert, Bruno Ségui, Yusuf A. Hannun, Jean Milhès, Julia Gilhodes, Virginie Garcia, Olivier Micheau, Pierre Brousset, Christopher J. Clarke, Marie Tosolini, Pierre Cordelier, Philippe Rochaix, Nicolas Meyer, Florie Bertrand, Nathalie Andrieu-Abadie, Sandrine Silvente-Poirot
Publikováno v:
Cancer Immunol Res
Cancer Immunology Research
Cancer Immunology Research, American Association for Cancer Research, 2021, 9 (5), pp.568-582. ⟨10.1158/2326-6066.CIR-20-0342⟩
Cancer Immunology Research, 2021, 9 (5), pp.568-582. ⟨10.1158/2326-6066.CIR-20-0342⟩
Cancer Immunology Research
Cancer Immunology Research, American Association for Cancer Research, 2021, 9 (5), pp.568-582. ⟨10.1158/2326-6066.CIR-20-0342⟩
Cancer Immunology Research, 2021, 9 (5), pp.568-582. ⟨10.1158/2326-6066.CIR-20-0342⟩
Dysregulation of lipid metabolism affects the behavior of cancer cells, but how this happens is not completely understood. Neutral sphingomyelinase 2 (nSMase2), encoded by SMPD3, catalyzes the breakdown of sphingomyelin to produce the anti-oncometabo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99931bf2f1e8a9e44fbcf9f063eafc44
https://europepmc.org/articles/PMC9631340/
https://europepmc.org/articles/PMC9631340/
Autor:
Silvia Arcucci, Sophie Tartare-Deckert, Corine Bertolotto, Justine Noujarède, Florian Rambow, Thierry Levade, Nathalie Andrieu-Abadie, Julia Gilhodes, Caroline Imbert, Stéphanie Brayer, Thomas Filleron, Nicolas Meyer, Jean-Christophe Marine, Bruno Ségui, Marie-Lise Bats, Virginie Garcia, Justine Leclerc, David Garandeau
Publikováno v:
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics, American Association for Cancer Research, 2019, 18 (2), pp.289-300. ⟨10.1158/1535-7163.MCT-17-1141⟩
Molecular Cancer Therapeutics, American Association for Cancer Research, 2019, 18 (2), pp.289-300. ⟨10.1158/1535-7163.MCT-17-1141⟩
BRAF inhibitors (BRAFi) are used to treat patients with melanoma harboring the V600E mutation. However, resistance to BRAFi is inevitable. Here, we identified sphingosine 1-phosphate (S1P) receptors as regulators of BRAFV600E-mutant melanoma cell-aut
Autor:
Vamsidhar Velcheti, Tony Mok, Thomas Filleron, Nir Peled, Ai Ni, Jürgen Wolf, Julie Milia, Dwight H. Owen, Jessica J. Lin, Bob T. Li, Benjamin Besse, Justin F. Gainor, Isabella Bergagnini, David P. Carbone, M. Offin, Julien Mazieres, Alexander Drilon, D. Ross Camidge, Mark M. Awad, Vaios Hatzoglou, Gregory J. Riely, Oliver Gautschi, Mark G. Kris
Publikováno v:
Journal of Thoracic Oncology. 13:1595-1601
Introduction In ret proto-oncogene (RET)–rearranged lung cancers, data on the frequency of brain metastases and, in particular, the outcomes of multikinase inhibitor therapy in patients with intracranial disease are not well characterized. Methods
Autor:
Caroline Imbert, Stéphane Carpentier, Nathalie Andrieu-Abadie, Marlène Marcellin, Marine Fraisse, Pierre Brousset, Florie Bertrand, Elodie Martin, Céline Colacios, Bruno Ségui, Philippe Rochaix, Odile Burlet-Schiltz, Nicolas Meyer, Virginie Garcia, Thierry Levade, Anne Montfort, Laurence Lamant, Anne Gonzalez de Peredo, Elie Marcheteau, Julia Gilhodes, Thomas Filleron, Florent Puisset, Sophie Tartare-Deckert
Publikováno v:
Nature Communications
Nature Communications, Nature Publishing Group, 2020, 11 (1), pp.437. ⟨10.1038/s41467-019-14218-7⟩
Nature Communications, Vol 11, Iss 1, Pp 1-14 (2020)
Nature Communications, 2020, 11 (1), pp.437. ⟨10.1038/s41467-019-14218-7⟩
Nature Communications 1 (11), 1-14. (2020)
Nature Communications, Nature Publishing Group, 2020, 11 (1), pp.437. ⟨10.1038/s41467-019-14218-7⟩
Nature Communications, Vol 11, Iss 1, Pp 1-14 (2020)
Nature Communications, 2020, 11 (1), pp.437. ⟨10.1038/s41467-019-14218-7⟩
Nature Communications 1 (11), 1-14. (2020)
Immune checkpoint inhibitors (ICIs) have dramatically modified the prognosis of several advanced cancers, however many patients still do not respond to treatment. Optimal results might be obtained by targeting cancer cell metabolism to modulate the i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bbb121baf2f7bbf6da6d7924779f762
https://www.hal.inserm.fr/inserm-02492179/file/s41467-019-14218-7.pdf
https://www.hal.inserm.fr/inserm-02492179/file/s41467-019-14218-7.pdf
Autor:
D Molnar-Stanciu, Etienne Chatelut, H Laharie-Mineur, E Suc, N. Dohollou, L. Venat-Bouvet, C Ferrer, H. Roche, D Franck, Frédéric Pinguet, P Marquet, Sandrine Lavau-Denes, C. Massabeau, Jacques Robert, Alexandre Evrard, V Mauries, Florence Dalenc, Marc Debled, Thomas Filleron, William Jacot
Publikováno v:
Cancer Research. 78:P3-12
Background: BC is a hormone-dependent disease for 75% of pts. HT is used in both adjuvant and metastatic settings for hormone–receptor (HR) positive tumors. In adjuvant situation, a 5-year HT period at least is recommended. Side-effects (SE) freque
Autor:
M. Jimenez, J-M Ferrero, Gaëlle Pierron, Frédéric Commo, Pascal Jézéquel, Amélie Lusque, V Attignon, A. Gonçalves, M. Campone, Ludovic Lacroix, C. Lefeuvre-Plesse, Florence Dalenc, Monica Arnedos, Isabelle Soubeyran, Thomas Bachelot, Ivan Bièche, Hervé Bonnefoi, M.P. Sablin, F Andre, Thomas Filleron
Publikováno v:
Cancer Research. 77:PD1-08
Background A genomic-driven therapeutic strategy in metastatic breast cancer (MBC) was recently demonstrated as feasible in the clinical practice, but its actual impact on patient outcome remains elusive. SAFIR02 study is an ongoing national multicen
Autor:
Fatima Bilal, Anne Montfort, Julia Gilhodes, Virginie Garcia, Joëlle Riond, Stéphane Carpentier, Thomas Filleron, Céline Colacios, Thierry Levade, Ahmad Daher, Nicolas Meyer, Nathalie Andrieu-Abadie, Bruno Ségui
Publikováno v:
Frontiers in Pharmacology
Frontiers in Pharmacology, Frontiers, 2019, 10, pp.443. ⟨10.3389/fphar.2019.00443⟩
Frontiers in Pharmacology, Vol 10 (2019)
Frontiers in Pharmacology, Frontiers, 2019, 10, pp.443. ⟨10.3389/fphar.2019.00443⟩
Frontiers in Pharmacology, Vol 10 (2019)
International audience; Sphingolipid (SL) metabolism alterations have been frequently reported in cancer including in melanoma, a bad-prognosis skin cancer. In normal cells, de novo synthesized ceramide is mainly converted to sphingomyelin (SM), the
Autor:
Remy Delva, Thomas Filleron, Fabienne Thomas, Marine Gross-Goupil, Christine Chevreau, Aude Flechon, Etienne Chatelut, Christophe Massart, Sotheara Moeung, Jean-Pierre Lotz, Gwenaelle Gravis, Laurence Gladieff, Julia Delahousse, Joseph Ciccolini, Isabelle Lochon, Bénédicte Lelièvre, Jacques-Olivier Bay, Vianney Poinsignon, Jérôme Guitton
Publikováno v:
Therapeutic Drug Monitoring
Therapeutic Drug Monitoring, Lippincott, Williams & Wilkins, 2019, 41 (1), pp.66-74. ⟨10.1097/FTD.0000000000000569⟩
Therapeutic Drug Monitoring, Lippincott, Williams & Wilkins, 2019, 41 (1), pp.66-74
Therapeutic Drug Monitoring, 2019, 41 (1), pp.66-74. ⟨10.1097/FTD.0000000000000569⟩
Therapeutic Drug Monitoring, Lippincott, Williams & Wilkins, 2019, 41 (1), pp.66-74. ⟨10.1097/FTD.0000000000000569⟩
Therapeutic Drug Monitoring, Lippincott, Williams & Wilkins, 2019, 41 (1), pp.66-74
Therapeutic Drug Monitoring, 2019, 41 (1), pp.66-74. ⟨10.1097/FTD.0000000000000569⟩
Background Therapeutic drug monitoring of carboplatin is based on its unbound clearance (CLU) determined by Bayesian analysis on unbound (U) concentrations. However, the ultrafiltration of plasma samples presents technical and time constraints. There
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad51f726af1411976c8802f27ebd3a3c
https://hal.univ-angers.fr/hal-02481351
https://hal.univ-angers.fr/hal-02481351